Stivarga Approval History
FDA Approved: Yes (First approved September 27, 2012)
Brand name: Stivarga
Generic name: regorafenib
Dosage form: Tablets
Company: Bayer HealthCare Pharmaceuticals Inc.
Treatment for: Colorectal Cancer, Gastrointestinal Stromal Tumor, Hepatocellular Carcinoma
Stivarga (regorafenib) is an oral multi-kinase inhibitor for the treatment of patients with metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma.
Development History and FDA Approval Process for Stivarga
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.